Literature DB >> 27680872

The Dual Role of PEDF in the Pathogenesis of OHSS: Negating Both Angiogenic and Inflammatory Pathways.

Irit Miller1, Dana Chuderland1, Hadas Grossman1, Raphael Ron-El1, Ido Ben-Ami1, Ruth Shalgi1.   

Abstract

CONTEXT: Ovarian hyperstimulation syndrome (OHSS) is a potentially life-threatening complication of assisted reproductive technologies. This complex syndrome is known to involve massive angiogenesis and inflammation. We have previously established the anti-angiogenic involvement of pigment epithelium-derived factor (PEDF) in the pathophysiology and treatment of OHSS.
OBJECTIVE: Evaluate the anti-inflammatory role of PEDF in OHSS.
DESIGN: In vivo mouse OHSS model and in vitro cultures of granulosa cells. MAIN OUTCOME: Changes in the expression of PEDF, IL-6, IL-8, and vascular endothelial growth factor (VEGF) were measured by quantitative PCR and ELISA; OHSS symptoms were recorded (body and ovarian weight gain and peritoneal vascular leakage quantified by the modified Miles's assay).
RESULTS: Rat granulosa cell-line stimulated with lysophosphatidic acid (LPA), exhibited a significant increase in IL-6 expression, concomitantly with a decrease in PEDF level (P < .01). Co-stimulation with recombinant PEDF (rPEDF) decreased the expression of IL-6 significantly (P < .05). Furthermore, the expression of IL-6 and IL-8 increased in LPA-stimulated human primary granulosa cells (P < .01). Co-stimulation with rPEDF decreased the expression of LPA-induced IL-6 and IL-8 mRNA and protein by 4- and 2- to 5-fold, respectively. IL-8-stimulated human primary granulosa cells exhibited increased expression of VEGF mRNA; co-stimulation with hCG induced a significantly higher increase in the expression of VEGF mRNA (P < .001), which was counteracted by rPEDF. Subcutaneous injection of 0.5 mg/kg rPEDF to OHSS-induced mice reduced the increased expression of IL-6 in the ovary (P < .01) and alleviated the severity of all OHSS parameters.
CONCLUSIONS: Our findings provide a framework that correlates down-regulation of OHSS symptoms caused by PEDF with both angiogenic and inflammatory pathways.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27680872     DOI: 10.1210/jc.2016-1744

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

Review 1.  Stress, Depression, Resilience and Ageing: A Role for the LPA-LPA1 Pathway.

Authors:  Roman Dario Moreno-Fernandez; Sara Tabbai; Estela Castilla-Ortega; Margarita Perez-Martin; Guillermo Estivill-Torrus; Fernando Rodriguez de Fonseca; Luis Javier Santin; Carmen Pedraza
Journal:  Curr Neuropharmacol       Date:  2018-03-05       Impact factor: 7.363

2.  Effect and Relationship of Seasons on the High Risk of Ovarian Hyperstimulation Syndrome After Oocyte Retrieval in Patients With Polycystic Ovary Syndrome.

Authors:  Yurong Cao; Hao Shi; Yue Ma; Linna Ma; Jun Zhai
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-26       Impact factor: 5.555

3.  Lipid Metabolic Disorders and Ovarian Hyperstimulation Syndrome: A Retrospective Analysis.

Authors:  Feifei Liu; Qi Jiang; Xuedong Sun; Yuzhen Huang; Zhenzhen Zhang; Ting Han; Yuhua Shi
Journal:  Front Physiol       Date:  2020-11-19       Impact factor: 4.566

4.  The Role of PEDF in Reproductive Aging of the Ovary.

Authors:  Luba Nemerovsky; Hadas Bar-Joseph; Anat Eldar-Boock; Rana Tarabeih; Cindy Elmechaly; Ido Ben-Ami; Ruth Shalgi
Journal:  Int J Mol Sci       Date:  2022-09-08       Impact factor: 6.208

5.  Kallistatin prevents ovarian hyperstimulation syndrome by regulating vascular leakage.

Authors:  Jianfang Huang; Yuling Mao; Quanxin Li; Honghai Hong; Ni Tang; Xiangjin Kang; Yuling Huang; Jianqiao Liu; Qing Gong; Yachao Yao; Lei Li
Journal:  J Cell Mol Med       Date:  2022-07-21       Impact factor: 5.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.